Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA. Read more about Wnt antagonist family genes as biomarkers for diagnosis, staging, and prognosis of renal cell carcinoma using tumor and serum DNA.
FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas. Read more about FGFR1 emerges as a potential therapeutic target for lobular breast carcinomas.
Chromosomal instability in microsatellite-unstable and stable colon cancer. Read more about Chromosomal instability in microsatellite-unstable and stable colon cancer.
Prognostic biomarkers in head and neck cancer. Read more about Prognostic biomarkers in head and neck cancer.
Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting. Read more about Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk. Read more about Effect of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis categorized by breast cancer risk.
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Read more about Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.
Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Read more about Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study.
Targeting the double-strand DNA break repair pathway as a therapeutic strategy. Read more about Targeting the double-strand DNA break repair pathway as a therapeutic strategy.
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Read more about Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas.
